Exploring cytokine dynamics in tuberculosis: A comparative analysis of patients and controls with insights from three-week antituberculosis intervention.

Autor: Krivošová M; Jessenius Faculty of Medicine in Martin, Biomedical Centre Martin, Comenius University Bratislava, Martin, Slovak Republic., Dohál M; Jessenius Faculty of Medicine in Martin, Biomedical Centre Martin, Comenius University Bratislava, Martin, Slovak Republic., Mäsiarová S; Jessenius Faculty of Medicine in Martin, Department of Pharmacology, Comenius University Bratislava, Martin, Slovak Republic., Pršo K; Jessenius Faculty of Medicine in Martin, Department of Pharmacology, Comenius University Bratislava, Martin, Slovak Republic., Gondáš E; Jessenius Faculty of Medicine in Martin, Department of Pharmacology, Comenius University Bratislava, Martin, Slovak Republic., Murín R; Jessenius Faculty of Medicine in Martin, Department of Medical Biochemistry, Comenius University Bratislava, Martin, Slovakia., Fraňová S; Jessenius Faculty of Medicine in Martin, Department of Pharmacology, Comenius University Bratislava, Martin, Slovak Republic., Porvazník I; National Institute for Tuberculosis, Lung Diseases and Thoracic Surgery, Vyšné Hágy, Slovak Republic.; Faculty of Health, Catholic University, Ružomberok, Slovak Republic., Solovič I; National Institute for Tuberculosis, Lung Diseases and Thoracic Surgery, Vyšné Hágy, Slovak Republic.; Faculty of Health, Catholic University, Ružomberok, Slovak Republic., Mokrý J; Jessenius Faculty of Medicine in Martin, Department of Pharmacology, Comenius University Bratislava, Martin, Slovak Republic.
Jazyk: angličtina
Zdroj: PloS one [PLoS One] 2024 Aug 29; Vol. 19 (8), pp. e0305158. Date of Electronic Publication: 2024 Aug 29 (Print Publication: 2024).
DOI: 10.1371/journal.pone.0305158
Abstrakt: Despite developing new diagnostics, drugs, and vaccines, treating tuberculosis (TB) remains challenging. Monitoring inflammatory markers can contribute to more precise diagnostics of TB, identifying its active and latent forms, or monitoring its treatment success. We assessed alterations in plasma levels of 48 cytokines in 20 patients (17 males) with active pulmonary TB compared to age-matched healthy controls (n = 18). Blood samples were collected from individuals hospitalised with TB prior to commencing antibiotic therapy, after the first week, and following the third week. The majority of patients received treatment with a combination of four first-line antituberculosis drugs: rifampicin, isoniazid, ethambutol, and pyrazinamide. Plasmatic cytokine levels from patients three times and controls were analyzed using a Bio-Plex Pro Human Cytokine Screening Panel. The results showed significantly higher levels of 31 cytokines (p<0.05) than healthy controls. Three-week therapy duration showed significantly decreased levels of nine cytokines: interferon alpha-2 (IFN-α2), interleukin (IL) 1 alpha (IL-1α), IL-1 receptor antagonist (IL-1ra), IL-6, IL-10, IL-12 p40, IL-17, leukemia inhibitory factor (LIF), and tumor necrosis factor alpha (TNF-α). Out of these, only levels of IL-1α and IL-6 remained significantly elevated compared to controls. Moreover, we have found a negative correlation of 18 cytokine levels with BMI of the patients but no correlation with age. Our results showed a clinical potential for monitoring the levels of specific inflammatory markers after a short treatment duration. The reduction in cytokine levels throughout the course of therapy could indicate treatment success but should be confirmed in studies with more individuals involved and a longer observation period.
Competing Interests: The authors have no conflicts of interest to declare.
(Copyright: © 2024 Krivošová et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje